Amneal Pharmaceuticals vs Bausch + Lomb
Amneal Pharmaceuticals (AMRX), health care, and Bausch + Lomb (BLCO), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Amneal Pharmaceuticals and Bausch + Lomb are valued at about the same: $7.4B and $7.4B. Amneal Pharmaceuticals's operating margin in its latest fiscal year was 13.1% and Bausch + Lomb's 2.22%. Over the past year Amneal Pharmaceuticals's share price has moved +83.5% and Bausch + Lomb's +38.3%.
Key facts
- Amneal Pharmaceuticals market value
- $7.4B
- Bausch + Lomb market value
- $7.4B
- Amneal Pharmaceuticals P/E
- 52.8
- Amneal Pharmaceuticals revenue
- $3BFY to 2025-12-31
- Bausch + Lomb revenue
- $5.1BFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Amneal Pharmaceuticals | Bausch + Lomb |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $7.4Blower | $7.4Bhigher |
| Revenue | $3Blower | $5.1Bhigher |
| Earnings | $72.1Mhigher | -$360Mlower |
| Employees | 8,700lower | 13,000higher |
| Total assets | $3.7Blower | $14Bhigher |
| Valuation | ||
| P/E | 52.8 | — |
| P/S | 2.4higher | 1.5lower |
| P/B | 13.8 | — |
| Dividend yield | 0.00% | — |
| Profitability | ||
| Operating margin | 13.1%higher | 2.22%lower |
| Balance sheet | ||
| Net assets | -$70.8Mlower | $6.4Bhigher |
| Total liabilities | $3.7Blower | $7.5Bhigher |
| Total debt | $2.6Blower | $5Bhigher |
| Cash on hand | $282Mlower | $383Mhigher |
| Price change | ||
| Today | -0.52%lower | -0.24%higher |
| 1 year | +83.5%higher | +38.3%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Amneal Pharmaceuticals only (0)
None of the tracked investors.
Bausch + Lomb only (4)
- Howard Marks1.1%
- Larry Robbins0.6%
- Carl Icahn0.4%
- Dan Loeb<0.1%
Percentages are each holding's share of that investor's reported portfolio. · Who owns BLCO
More on Amneal Pharmaceuticals
Further comparisons
Amneal Pharmaceuticals against its closest peers
Bausch + Lomb against its closest peers
Learn
Questions and answers
Which is bigger, Amneal Pharmaceuticals or Bausch + Lomb?
By market value, Bausch + Lomb is the larger: $7.4B against $7.4B for Amneal Pharmaceuticals. By revenue in its latest fiscal year, Bausch + Lomb is the larger: $5.1B against $3B for Amneal Pharmaceuticals.
Which has the higher operating margin?
Amneal Pharmaceuticals: 13.1%, against 2.22% for Bausch + Lomb. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has more debt?
Bausch + Lomb: $5B, against $2.6B for Amneal Pharmaceuticals. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Amneal Pharmaceuticals and Bausch + Lomb?
None of the tracked superinvestors holds both in their latest 13F filing. 0 hold Amneal Pharmaceuticals and 4 hold Bausch + Lomb.
Cite this page
Funkfolio, “Amneal Pharmaceuticals vs Bausch + Lomb”, data as of 17 November 2026. https://funkfolio.com/compare/amrx-vs-blco
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.